Advance Capital Management Inc. Has $244,000 Stake in Pfizer Inc. (NYSE:PFE)

Advance Capital Management Inc. lessened its position in Pfizer Inc. (NYSE:PFE) by 7.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,208 shares of the biopharmaceutical company’s stock after selling 744 shares during the period. Advance Capital Management Inc.’s holdings in Pfizer were worth $244,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PFE. Private Advisor Group LLC boosted its position in Pfizer by 12.8% during the second quarter. Private Advisor Group LLC now owns 735,962 shares of the biopharmaceutical company’s stock worth $20,592,000 after purchasing an additional 83,754 shares during the period. Lake Street Advisors Group LLC grew its stake in Pfizer by 29.3% in the 2nd quarter. Lake Street Advisors Group LLC now owns 35,090 shares of the biopharmaceutical company’s stock valued at $982,000 after buying an additional 7,955 shares during the last quarter. Wakefield Asset Management LLLP bought a new position in Pfizer in the 2nd quarter valued at about $454,000. Strategic Financial Concepts LLC bought a new stake in shares of Pfizer during the second quarter worth approximately $38,000. Finally, Asset Dedication LLC grew its holdings in Pfizer by 4.2% in the 2nd quarter. Asset Dedication LLC now owns 16,695 shares of the biopharmaceutical company’s stock valued at $467,000 after buying an additional 669 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 1.1 %

NYSE:PFE traded up $0.29 during trading hours on Monday, hitting $26.88. 43,801,648 shares of the company were exchanged, compared to its average volume of 32,645,211. The stock has a market capitalization of $152.33 billion, a price-to-earnings ratio of 36.32, a price-to-earnings-growth ratio of 0.63 and a beta of 0.65. The company has a fifty day simple moving average of $26.33 and a 200 day simple moving average of $28.08. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.17) earnings per share. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.40%. Pfizer’s dividend payout ratio is presently 232.43%.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have weighed in on PFE shares. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Finally, Guggenheim cut their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.15.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.